We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

74 hedge funds and large institutions have $100M invested in Gyre Therapeutics in 2013 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 20 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more call options, than puts

Call options by funds: $2.04M | Put options by funds: $1.02M

20% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 20

0% more funds holding

Funds holding: 74 → 74 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 14

25% less capital invested

Capital invested by funds: $135M → $100M (-$34.1M)

Holders
74
Holders Change
–
Holders Change %
0%
% of All Funds
2.15%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
24
Reduced
20
Closed
14
Calls
$2.04M
Puts
$1.02M
Net Calls
+$1.01M
Net Calls Change
+$4.36M

Top Buyers

1
DM
Deerfield Management
New York
+$3.09M
2
BIT
BlackRock Institutional Trust
California
+$1.5M
3
BC
Broadfin Capital
New York
+$1.5M
4
Goldman Sachs
Goldman Sachs
New York
+$1.1M
5
CCM
Camber Capital Management
Massachusetts
+$926K

Top Sellers

1
BBA
Baker Bros. Advisors
New York
-$11M
2
BFA
BlackRock Fund Advisors
California
-$1.99M
3
Deutsche Bank
Deutsche Bank
Germany
-$1.79M
4
Millennium Management
Millennium Management
New York
-$1.17M
5
HVC
Healthcare Value Capital
New Jersey
-$1.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
Jacobs Levy Equity Management
51
Jacobs Levy Equity Management
New Jersey
$135K -$193K -49 -54%
NFA
52
Nationwide Fund Advisors
Ohio
$129K – – –
AllianceBernstein
53
AllianceBernstein
Tennessee
$119K -$31.5K -8 -18%
BGIM
54
Brandywine Global Investment Management
Pennsylvania
$116K +$138K +35 New
Susquehanna International Group
55
Susquehanna International Group
Pennsylvania
$102K +$122K +31 New
Prudential Financial
56
Prudential Financial
New Jersey
$87K -$3.94K -1 -4%
VKH
57
Virtu KCG Holdings
New York
$81K +$98.6K +25 New
DekaBank Deutsche Girozentrale
58
DekaBank Deutsche Girozentrale
Germany
$79K – – –
AIG
59
American International Group
New York
$79K – – –
PL
60
Parkwood LLC
Ohio
$75K +$90.7K +23 New
ARTA
61
A.R.T. Advisors
New York
$71K -$67K -17 -44%
LMF
62
LMR Master Fund
Cayman Islands
$69K +$82.8K +21 New
CCMH
63
Cornerstone Capital Management Holdings
New York
$67K -$166K -42 -67%
NI
64
Numeric Investors
Massachusetts
$66K -$248K -63 -76%
Barclays
65
Barclays
United Kingdom
$55K +$43.4K +11 +157%
PP
66
PDT Partners
New York
$53K +$11.8K +3 +23%
Citigroup
67
Citigroup
New York
$51K +$3.94K +1 +7%
Bank of America
68
Bank of America
North Carolina
$33K -$7.88K -2 -17%
Citadel Advisors
69
Citadel Advisors
Florida
$12K – – –
BNP Paribas Financial Markets
70
BNP Paribas Financial Markets
France
$5.65K +$7.88K +2 New
GT
71
Glenmede Trust
Pennsylvania
$5K – – –
U
72
UBS
Switzerland
$4K +$3.94K +1 New
JAM
73
Jolley Asset Management
North Carolina
$2K – – –
BJ
74
BlackRock Japan
Japan
$1K – – –
Manulife (Manufacturers Life Insurance)
75
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$96 +$39.4K +10 +53%
1 2
3
4

GYRE Hedge Fund Activity: Q4 2013 in Review

74 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q4 2013, worth a combined $100M — down 25% from $135M a quarter earlier.

Fund positioning in GYRE was balanced in Q4 2013: 14 funds opened new positions, 14 closed out, 24 added to existing stakes and 20 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $3.09M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $11M sold.

  • 74 institutional investors held Gyre Therapeutics (GYRE) as of Q4 2013, unchanged from Q3 2013.
  • Funds reported $100M of Gyre Therapeutics stock for Q4 2013, down 25% quarter-over-quarter.
  • 14 funds opened new Gyre Therapeutics positions in Q4 2013 and 14 closed out, a net change of 0 holders.
  • The largest Gyre Therapeutics buyer in Q4 2013 was Deerfield Management, an estimated $3.09M added.
  • The largest Gyre Therapeutics seller in Q4 2013 was Baker Bros. Advisors, an estimated $11M sold.

Based on aggregated 13F filings for Q4 2013.